Detalhe da pesquisa
1.
Noninvasive detection of any-stage cancer using free glycosaminoglycans.
Proc Natl Acad Sci U S A;
119(50): e2115328119, 2022 12 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36469776
2.
suPARnostic: an advanced predictive tool for detecting recurrence in renal cell carcinoma.
BMC Urol;
23(1): 168, 2023 Oct 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37875832
3.
Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?
BJU Int;
128(3): 386-394, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33794055
4.
Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma.
World J Urol;
39(10): 3823-3831, 2021 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33851271
5.
Follow-up after curative treatment of localised renal cell carcinoma.
World J Urol;
36(12): 1953-1959, 2018 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29767327
6.
Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study.
World J Urol;
34(8): 1081-6, 2016 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26847337
7.
Metastasis therapies for renal cancer.
Curr Opin Urol;
26(6): 566-72, 2016 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27471993
8.
Local treatments for metastases of renal cell carcinoma: a systematic review.
Lancet Oncol;
15(12): e549-61, 2014 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25439697
9.
Incidence and associated risk factors of venous thromboembolism after open and laparoscopic partial nephrectomy in patients administered short-period thromboprophylaxis: a Danish nationwide population-based cohort study.
Scand J Urol;
57(1-6): 81-85, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36703546
10.
A protocol for the development of core outcome sets for effectiveness trials and clinical audits in renal cell cancer (R-COS).
BJUI Compass;
4(5): 504-512, 2023 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37636213
11.
Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups.
Eur Urol Open Sci;
47: 65-72, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36601038
12.
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.
Eur Urol;
83(1): 10-14, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36511268
13.
A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer.
Eur Urol Open Sci;
48: 1-11, 2023 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36578462
14.
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel.
Eur Urol;
83(1): 3-5, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36253306
15.
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View.
Eur Urol;
83(2): 97-100, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36435661
16.
The Benefits and Harms of Pharmacological Treatment for Postradiation Pelvic Pain: A Systematic Review by the European Association of Urology Chronic Pelvic Pain Panel with Recommendations for Clinical Practice.
Eur Urol Open Sci;
56: 29-38, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37711669
17.
Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma-A Prospective Cohort Study.
Eur Urol Open Sci;
42: 30-39, 2022 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35911082
18.
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.
Eur Urol;
82(4): 399-410, 2022 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35346519
19.
The Benefits and Harms of Botulinum Toxin-A in the Treatment of Chronic Pelvic Pain Syndromes: A Systematic Review by the European Association of Urology Chronic Pelvic Pain Panel.
Eur Urol Focus;
8(1): 320-338, 2022 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33526405
20.
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.
Eur Urol;
81(2): 134-137, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34920897